tak-954
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2017 (NCT03173170)
Timeline
Indications
Mechanism of action
- Serotonin 4 (5-HT4) receptorAGONIST
HTR4 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tak-954
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03870555 | Phase 1 | Mar 8, 2019 | Millennium Pharmaceuticals |
| NCT03827655 | Phase 2 | Mar 7, 2019 | Millennium Pharmaceuticals |
| NCT03477903 | Phase 2 | Aug 25, 2018 | Millennium Pharmaceuticals |
| NCT03500224 | Phase 1 | Apr 30, 2018 | Millennium Pharmaceuticals |
| NCT03281577 | Phase 2 | Jan 2, 2018 | Takeda |
| NCT03296787 | Phase 1 | Nov 21, 2017 | Takeda |
| NCT03277274 | Phase 1 | Nov 9, 2017 | Takeda |
| NCT03173170 | Phase 1 | May 31, 2017 | Takeda |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Millennium Pharmaceuticals | For profit | 4 | 4 | 2 | 2018 |
| Takeda | For profit | 4 | 4 | 2 | 2017 |
2 organizations
Page 1 / 1